AGENDA

POETIC Summer Meeting
July 26th – 27th, 2018
Banff Centre for Arts & Creativity
Banff, Alberta Canada

WEDNESDAY, JULY 25

EVENING SESSION
4:00 PM MT (6:00 PM EST) | Banff Centre for Arts & Creativity | Room KC204

4:00 PM MT (6:00 EST)  BOARD OF DIRECTORS MEETING  (Closed Meeting)

5:00 PM  DINNER  
Board of Directors

THURSDAY, JULY 26

MORNING SESSION
7:30 AM – 1:15 PM | Banff Centre for Arts & Creativity | Room KC203

7:30 – 8:15 AM  REGISTRATION/BREAKFAST  
Vistas Dining Room

GREETINGS/INTRODUCTIONS
Aru Narendran, MD, PhD, Alberta Children’s Hospital  
Victor Lewis, MD, Division Head, Hematology/Oncology and Bone Marrow Transplantation, Alberta Children’s Hospital

WELCOME ADDRESS
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center  
Co-Founder and Director, POETIC
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 9:30 AM</td>
<td>KEYNOTE ADDRESS</td>
<td><em>Immune Modulation by the Extracellular Matrix</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pinaki Bose, PhD, Director, Tumour Biology and Translational Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Calgary</td>
</tr>
<tr>
<td>8:30 – 9:00 AM</td>
<td><strong>Tackling Intra-Tumor Heterogeneity for Precision Medicine: Challenges and Opportunities</strong></td>
<td>Sorana Morrissy, PhD, Assistant Professor, Department of Biochemistry &amp; Molecular Biology, Cumming School of Medicine, University of Calgary</td>
</tr>
<tr>
<td>9:00 – 9:30 AM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>9:35 AM – 12:35 PM</td>
<td><strong>THERAPEUTIC STRATEGIES FOR TARGETED DELIVERY</strong></td>
<td></td>
</tr>
<tr>
<td>9:35 – 10:35 AM</td>
<td><strong>Preclinical Development of miR loaded Exosomal Vesicles</strong></td>
<td>Stephen Gould, PhD, Professor Biologic Chemistry, Johns Hopkins University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Lyden, MD, PhD, Weill Cornell Medical Center</td>
</tr>
<tr>
<td>10:35 – 11:35 AM</td>
<td><strong>Downstream Analysis of miR loaded Exosomal Vesicles</strong></td>
<td>Olga Kovalchuk, MD, PhD, University of Lethbridge</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bodour Salhia, PhD, University of Southern California</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center*</td>
</tr>
<tr>
<td>11:35 AM – 12:05 PM</td>
<td><strong>Preclinical &amp; Clinical Development of Taurolidine NanoPro™</strong></td>
<td>Tony Pfaffle, MD, Chief Scientific Officer, Cormedix, Inc.</td>
</tr>
<tr>
<td>12:05 – 12:35 PM</td>
<td><strong>POETIC International Initiative</strong></td>
<td>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Lyden, MD, PhD, Weill Cornell Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bodour Salhia, PhD, University of Southern California</td>
</tr>
<tr>
<td>12:35 – 1:15 PM</td>
<td><strong>LUNCH</strong></td>
<td>Vistas Dining Room</td>
</tr>
<tr>
<td>1:15 – 5:00 PM</td>
<td><strong>AFTERNOON SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>1:15 – 3:15 PM</td>
<td><strong>THERAPEUTIC STRATEGIES EXPLORING IMUNOTHERAPEUTIC APPROACHES</strong></td>
<td></td>
</tr>
<tr>
<td>1:15 – 2:15 PM</td>
<td><strong>Preclinical Development of PV-10</strong></td>
<td>Eric Wachter, PhD, Chief Technology Officer and Director</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provectus Biopharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aru Narendran, MD, PhD, Alberta Children’s Hospital</td>
</tr>
<tr>
<td>1:15 – 2:15 PM</td>
<td><strong>Clinical Development of PV-10</strong></td>
<td>Eric Wachter, PhD, Chief Technology Officer and Director</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provectus Biopharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Todd Heaton, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
</tbody>
</table>
### 2:15 – 3:15 PM
**Myeloid-lineage p53 As a Novel Target for Immunotherapy**
David Munn, MD, Pediatric Immunotherapy Program
Medical College of Georgia

### 3:15 – 3:30 PM
**BREAK**

### 3:30 – 4:30 PM
**iMATRIX Trials: Clinical update**
Stephen Simko, MD, Medical Director
Innovative Pediatric Oncology Drug Development, Genentech

### 4:30 – 5:00 PM
**CLINICAL TRIALS UNDER DEVELOPMENT**

**Selinexor/Cabazitaxel Concept**
Norman Lacayo, MD, Lucile Packard Children’s Hospital

### 5:00 – 5:15 PM
**PHARMACY UPDATE**
Morad Balas, Clinical Coordinator for Pharmacy Services
Memorial Sloan Kettering Cancer Center

### 5:15 PM
**MEETING ADJOURN**

### 6:00 PM
**DINNER**
Banff Centre for Arts & Creativity | Room KC201

---

### FRIDAY, JULY 27

#### MORNING SESSION
7:30 AM – 1:15 PM | Banff Centre for Arts & Creativity | Room KC203

### 7:30 – 8:00 AM
**REGISTRATION/BREAKFAST**
Vistas Dining Room

### 8:00 – 8:40 AM
**PI Meeting (Closed Session)**
Tanya Trippett, MD, Co-Founder and Director POETIC
Cynthia Herzog, MD, MD Anderson Cancer Center
Lisa McGregor, MD, Pennsylvania State Medical Center
Joseph DeStefano, Research Program Director, POETIC

### 8:40 – 10:40 AM
**POETIC Translational Genomics Program**

**Translational Genomics of Neuroblastoma: New Findings**
David Lyden, MD, PhD, Weill Cornell Medical Center
Olga Kovalchuk, MD, PhD, University of Lethbridge
Bodour Salhia, PhD, University of Southern California
Michael Berger, PhD, Memorial Sloan Kettering Cancer Center*
Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center*

8:40 – 9:40 AM *Will be attending via conference call.*
**Translational Genomics of Osteosarcoma: New Findings**
David Lyden, MD, PhD, Weill Cornell Medical Center
Olga Kovalchuk, MD, PhD, University of Lethbridge
Bodour Salhia, PhD, University of Southern California
Michael Berger, PhD, Memorial Sloan Kettering Cancer Center*
Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center*

9:40 – 10:40 AM

*BWill be attending via conference call.

---

10:40 – 10:45 AM

**BREAK**

10:45 – 11:15 AM

**cBioPortal: Clinician Interface**
Angelica Ochoa, PhD, Memorial Sloan Kettering Cancer Center

11:15 AM – 12:15 PM

**PEDIATRIC CANCER MODELING**

11:15 – 11:45 AM

**Organoids**
Michele Cioffi, PhD, Weill Cornell Medical Center

11:45 AM – 12:15 PM

**Multi-Parallel Molecular and Immunologic Profiling in Relapsed/Refractory Pediatric Tumors – A Multicenter POETIC Biology Study**
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
Norman Lacayo, MD, Lucile Packard Children’s Hospital

---

12:15 – 1:15 PM

**LUNCH**
Vistas Dining Room

---

**AFTERNOON SESSION**

1:15 – 4:15 PM | Banff Centre for Arts & Creativity | Room KC203

1:15 – 2:45 PM

**ABSTRACT PRESENTATIONS**

1:15 – 1:45 PM

**Clinical Abstract Presentations**
10 Minute Presentations each (3)

1:45 – 2:45 PM

**Biology Abstract Presentations**
10 Minute Presentations each (6)

2:45 – 2:50 PM

**BREAK**

2:50 – 3:20 PM

**Tolero Pipeline: TP-0184 in DIPG**
Steve Weitman, MD, PhD, University of Texas Health Sciences Center

3:20 – 3:40 PM

**Larotrectinib for Pediatric Solid Tumors Harbouring NTRK Gene Fusions**
Josh Silvertown PhD, MBA, MSM, Medical Affairs Strategist – Oncology
Bayer Inc., Medical & Scientific Affairs, Pharmaceuticals
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40 – 4:10 PM</td>
<td>ACTIVE CLINICAL TRIALS</td>
</tr>
</tbody>
</table>
| 3:40 – 3:55 PM | *Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide*  
PI: Jessica Boklan, MD, Phoenix Children’s Hospital |
| 3:55 – 4:10 PM | *Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session)*  
PI: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center |
| 4:10 – 4:15 PM | OUTTAKE                                      |
| 4:15 PM       | ADJOURN                                      |